Friday, 31 July 2015


Stephen and others

Phase 1 trials of ICT-107 looked very promising and I know phase 2 trials were started a few years back.  Any updates on how this is progressing?


1 comment:

  1. Latest press release regarding the randomized phase 2 trial of ICT-107 is here:

    Patients with either HLA-A1 or HLA-A2 positivity were allowed in the trial, but what they found is that the vaccine was only effective for patients who were HLA-A2 positive. The results for that group have been very good (esp for those with MGMT methylation), and they are moving to a phase 3 trial soon (last quarter 2015).